J&J, states settle on Risperdal

As part of a $181-million settlement with states to resolve charges of improper marketing and advertising, Johnson & Johnson agreed to stop several practices regarding Ripserdal and its cousin Invega.

These include misusing CME programs for marketing; awarding grants to doctors based on prescribing habits; presenting information that is not scientifically sound; and disseminating reprints with off-label usage information.

At press time, J&J was expected to pay up to $2.2 billion for the same allegations by DOJ involving these and other drugs.

On its website, J&J said it's not admititng any Risperdal wrongdoing.

The most recent MM&M Skill Sets Live event, "Personalizing the Healthcare Experience," surveyed a range of issues relating to some of the industry's hottest topics. This e-book conveys a wealth of information and opinion designed to help marketers demystify the challenges associated with the personalization of healthcare messaging. Click here to access.